Basel, 12 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new clinical and real-world data for OCREVUS® (ocrelizumab), demonstrating its role in continuing to transform care for ...

Initiation of OCREVUS as first-line treatment reduces relapses, hospitalisations and costs compared with using OCREVUS in second-line setting Nine-year long-term safety data for OCREVUS further ...

Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeks OCREVUS subcutaneous injection was comparable to ...

– 75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to Ocrevus in open-label ...

– 75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression (NEP) in a one-year interim analysis of CONSONANCE study – ...

10-year efficacy data highlight OCREVUS’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS) 10-year safety data ...

– 77% of early-stage relapsing-remitting multiple sclerosis (RRMS) patients who had not received prior treatment achieved no evidence of disease activity (NEDA) at two years – – Initiation of Ocrevus ...

– 10-year efficacy data highlight Ocrevus’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS) – – More than 3,200 ...